Toronto 
Health Canada has approved the first clinical trials in Canada of a potential COVID-19 vaccine at Dalhousie University in Nova Scotia.
This news was announced by Trudeau today during his daily press briefing from Rideau Cottage.
The trial will take place at the Canadian Centre for Vaccinology at Dalhousie University.
The National Research Council of Canada (NRC) announced a collaboration with CanSino Biologics Inc. (CanSinoBIO) to advance bioprocessing and clinical development in Canada of a candidate vaccine against COVID-19 on May 12th.
As per the press release, the vaccine candidate, Ad5-nCoV, was developed using technology from both China and Canada. It was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSino Biologics Inc. using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein, which is grown using living cells that were designed and developed at the National Research Council of Canada.
CanSino Biologics and the NRC in collaboration with the Canadian Immunization Research Network at the Canadian Center for Vaccinology will be conducting the vaccine trails.
